General
Preferred name
proguanil
Synonyms
CHLOROGUANIDE HYDROCHLORIDE ()
1-(4-Chlorophenyl)-5-isopropyl-biguanide hydrochloride ()
Proguanil D6 ()
Paludrine hydrochloride ()
Chlorguanide hydrochloride ()
Chloroquanil ()
Proguanil hydrochloride ()
CHLOROGUANIDE ()
Proguanil (hydrochloride) ()
chlorguanide, chloroguanide ()
Drinupal ()
Proguanil hcl ()
Proguanil hydrochloride component of malarone ()
Diguanyl ()
RP-3359 ()
Guanatol ()
SN-12837 ()
Paludrine ()
336U50 ()
Proguanili hydrochloridum ()
M-4888 ()
NSC-12977 ()
336-U-50 ()
GW AH7673A ()
Palusil ()
GW-AH7673A ()
GWAH7673A ()
NSC-26614 ()
Proguanil hydrochloride component of malarone pediatric ()
Chlorguanide ()
P&D ID
PD009789
CAS
637-32-1
46920-30-3
500-92-5
Tags
available
drug
prodrug
Approved by
FDA
First approval
2000
Drug indication
Malaria
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Proguanil hydrochloride, an antimalarial proagent, is metabolized to the active metabolite Cycloguanil (HY-12784). Proguanil hydrochloride is a dihydrofolate reductase (DHFR) inhibitor[1][2].
PRICE
36
DESCRIPTION
Proguanil is a biguanide derivative that, once administered, is converted to the active metabolite . It is an antimalarial drug, used in combination with or with .
The marketed formulations contain proguanil hydrochloride (PubChem CID 9570076).
(GtoPdb)
The marketed formulations contain proguanil hydrochloride (PubChem CID 9570076).
(GtoPdb)
DESCRIPTION
Proguanil is a biguanide derivative that, once administered, is converted to the active metabolite cycloguanil. It is an antimalarial drug, used in combination with or with .
Proguanil is one of the antimalarials listed in the WHO 20th Essential Medicines List (2017).
Proguanil is one of the antimalarials listed in the WHO 20th Essential Medicines List (2017).
DESCRIPTION
Proguanil is a biguanide derivative that, once administered, is converted to the active metabolite cycloguanil. It is an antimalarial drug, used in combination with or with .
The marketed formulations contain proguanil hydrochloride (PubChem CID 9570076).
Proguanil is one of the antimalarials listed in the WHO 20th Essential Medicines List (2017).
The marketed formulations contain proguanil hydrochloride (PubChem CID 9570076).
Proguanil is one of the antimalarials listed in the WHO 20th Essential Medicines List (2017).
DESCRIPTION
Proguanil, an antimalarial proagent, is metabolized to the active metabolite Cycloguanil (HY-12784). Proguanil is a dihydrofolate reductase (DHFR) inhibitor[1][2].
PRICE
35
DESCRIPTION
Proguanil (Chloroguanide) is a prophylactic antimalarial drug that acts primarily through its active metabolite, Cycloguanil, which inhibits the dihydrofolate reductase (DHFR) enzyme of Plasmodium falciparum, preventing the synthesis of purines and pyrimidines and inhibiting the growth and reproduction of the parasite.
DESCRIPTION
Proguanil hydrochloride is the hydrochloride salt form of proguanil, which is a synthetic biguanide derivative of pyrimidine. It is used as an folate antagonist with antimalarial property. It is used to treat and prevent malaria together with chloroquine or atovaquone. lt is converted by the liver to its active metabolite, cycloguanil. It may be used in anti-parasitic protozoan drug development to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an antimalarial drug. It was developed by AstraZeneca and has been listed.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Proguanil hydrochloride (Chloroquanil) is a biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.Upon hydrolysis, Proguanil hydrochloride is converted to its active cyclic triazine metabolite, cycloguanil, by a cytochrome P450 dependent reaction. Cycloguanil selectively inhibits the bifunctional dihydrofolate reductase-thymidylate synthase of plasmodium parasite, thereby disrupting deoxythymidylate synthesis and ultimately blocking DNA and protein synthesis in the parasite.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
1
Compound Sets
25
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
115
Molecular Weight
253.11
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
5
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
2.21
TPSA
83.79
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
6.0
QED
0.41
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Parasite
Dihydrofolate reductase
Antifolate
NADH dehydrogenase
Thymidylate Synthase
DHFR
Anti-infection,DHFR
Pathway
Anti-infection
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Metabolism
Microbiology/virology
Cell Cycle/DNA Damage
MOA
protozoal dihydrofolate reductase inhibitor
dihydrofolate reductase inhibitor
Indication
malaria
Therapeutic Class
Antimalarials
Solubility
Acetonitrile: water: ~1 mg/mL (60/40)
Source data

